Trial · NCT02563353
PTH and Vibration in OSteoporosis Study
NCT02563353, Not applicable, Completed, Odense University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PTH and Vibration in OSteoporosis Study. Trials, record NCT02563353. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02563353
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PTH and Vibration in OSteoporosis Study
- NCT number
- NCT02563353
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 35 participants, actual
- Lead sponsor
- Odense University Hospital
- Conditions
- Osteoporosis
- Interventions
- whole-body vibration, teriparatide
- First posted
- 2015-09-30
- Last updated
- 2020-09-18
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in the BMD, Bone Mineral Density of hip and spine region (Hologic DXA machine) | at the time the participants start treatment and in an interval as close as possible to after 6, 12, 18, 24 months from baseline | DXA scan of hip and spine regions, BMD (g/cm\^2) |
| Secondary | Changes in the Bone microarchitecture at the tibia | at the time the participants start treatment and in an interval as close as possible to after 6, 12, 18 and 24 months from baseline | HRpQCT assesses parameters of bone microarchitecture at the tibia. |
| Secondary | Changes in the Bone microarchitecture at the radius | at the time the participants start treatment and in an interval as close as possible to after 6, 12, 18 and 24 months from baseline | HRpQCT assesses parameters of bone microarchitecture at the radius. |
| Secondary | changes in muscle mass | at the time the participants start treatment and in an interval as close as possible to after 12 and 24 months from baseline | Full body DXA |
| Secondary | Changes from baseline in the markers of bone resorption | at the time the participants start treatment and in an interval as close as possible to after 3, 6, 12, 18, 24 months from baseline | CTX, sclerostin |
| Secondary | Changes from baseline in the markers of bone formation | at the time the participants start treatment and in an interval as close as possible to after 3, 6, 12, 18, 24 months from baseline | P1NP |
| Secondary | Changes in Muscle strength | at the time the participants start treatment and in an interval as close as possible to after 3,6,12,18 and 24 months from baseline | Measurements of muscle strength (leg extensor power) |
| Secondary | Changes in handgrip strength | at the time the participants start treatment and in an interval as close as possible to after 3,6,12,18 and 24 months from baseline | Measurements of muscle strength (handgrip strength) |
| Secondary | Changes in Balance | at the time the participants start treatment and in an interval as close as possible to after 3, 6 ,12, 18 and 24 months from baseline | Short Physical Performance Battery (SPPB) |
| Secondary | Adherence to WBV | During 2 years from the start of the treatment | Self Reporting training log |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers44
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02563353
GET https://conductscience.org/api/trials/v1/NCT02563353/papers?page=2